TGTX [NASD]
TG Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.78 Insider Own1.10% Shs Outstand135.33M Perf Week21.66%
Market Cap2.61B Forward P/E- EPS next Y-1.13 Insider Trans-1.25% Shs Float133.34M Perf Month72.43%
Income-238.70M PEG- EPS next Q-0.27 Inst Own69.70% Short Float / Ratio16.92% / 4.07 Perf Quarter200.00%
Sales5.00M P/S522.36 EPS this Y-8.70% Inst Trans-5.91% Short Interest22.56M Perf Half Y183.15%
Book/sh0.74 P/B23.46 EPS next Y18.70% ROA-82.90% Target Price19.11 Perf Year73.96%
Cash/sh1.17 P/C14.84 EPS next 5Y- ROE-149.90% 52W Range3.48 - 18.31 Perf YTD49.11%
Dividend- P/FCF- EPS past 5Y-10.50% ROI-113.00% 52W High-3.66% Beta2.09
Dividend %- Quick Ratio5.00 Sales past 5Y113.10% Gross Margin90.60% 52W Low406.90% ATR1.12
Employees186 Current Ratio5.00 Sales Q/Q-95.00% Oper. Margin- RSI (14)74.82 Volatility8.10% 8.25%
OptionableYes Debt/Eq0.70 EPS Q/Q59.10% Profit Margin- Rel Volume0.80 Prev Close17.36
ShortableYes LT Debt/Eq0.70 EarningsNov 10 BMO Payout- Avg Volume5.54M Price17.64
Recom2.20 SMA2028.10% SMA5063.76% SMA200141.59% Volume937,353 Change1.61%
May-20-22Initiated BofA Securities Underperform $5
Feb-23-22Reiterated B. Riley Securities Buy $49 → $35
Nov-15-21Downgrade Goldman Neutral → Sell $33 → $26
Apr-20-21Initiated Goldman Neutral $50
Apr-19-21Reiterated H.C. Wainwright Buy $79 → $89
Sep-01-20Initiated JP Morgan Overweight $38
Aug-11-20Reiterated H.C. Wainwright Buy $32 → $38
Jun-05-20Initiated Evercore ISI Outperform $60
Jan-17-20Reiterated H.C. Wainwright Buy $20 → $24
Nov-27-19Resumed B. Riley FBR Buy $12
Show Previous Ratings
Jan-30-23 06:00PM
Jan-26-23 07:00AM
Jan-18-23 07:22AM
Jan-12-23 06:00PM
07:06AM
12:00PM Loading…
Jan-09-23 12:00PM
06:31AM
Jan-06-23 07:30AM
Dec-30-22 05:27PM
11:45AM
09:30AM
Dec-29-22 02:47PM
10:39AM
Dec-28-22 06:35PM
01:48PM
01:23PM Loading…
01:23PM
Dec-08-22 09:35PM
Dec-02-22 09:55AM
Nov-24-22 06:49AM
Nov-21-22 08:48AM
Nov-16-22 12:00PM
09:55AM
Nov-12-22 07:43AM
Nov-11-22 07:48PM
Nov-10-22 05:04PM
08:45AM
07:30AM
Nov-08-22 07:30AM
Oct-26-22 07:30AM
Oct-19-22 08:55AM
07:30AM Loading…
Oct-13-22 07:30AM
Sep-11-22 07:00AM
Sep-09-22 07:30AM
Aug-29-22 09:55AM
Aug-25-22 12:32PM
07:30AM
Aug-12-22 09:55AM
Aug-11-22 08:03AM
Aug-08-22 08:45AM
07:30AM
Aug-05-22 07:30AM
Jun-27-22 07:30AM
Jun-22-22 07:43AM
Jun-12-22 10:17AM
Jun-09-22 09:20AM
Jun-03-22 07:30AM
Jun-01-22 02:22PM
09:35AM
May-31-22 07:30AM
May-26-22 07:30AM
May-20-22 07:30AM
May-12-22 08:34AM
May-05-22 08:15AM
May-03-22 07:45AM
May-02-22 03:00PM
Apr-26-22 07:30AM
Apr-19-22 11:02AM
Apr-18-22 03:34PM
10:17AM
06:00AM
Apr-15-22 08:30AM
Apr-06-22 07:30AM
Apr-04-22 07:44AM
Mar-10-22 08:15AM
Mar-04-22 08:56AM
07:30AM
Mar-03-22 11:27AM
08:00AM
Mar-01-22 08:45AM
07:30AM
Feb-25-22 07:30AM
Feb-24-22 08:05AM
07:30AM
Feb-15-22 10:09AM
07:30AM
Jan-31-22 02:04AM
Jan-27-22 12:30PM
Jan-24-22 07:30AM
Jan-07-22 05:38PM
Jan-05-22 07:30AM
Jan-04-22 07:30AM
Jan-03-22 01:59PM
Dec-18-21 02:38AM
Dec-16-21 04:00PM
Dec-14-21 07:50PM
07:30AM
07:15AM
Dec-13-21 10:40AM
07:30AM
Dec-12-21 10:42PM
Dec-10-21 07:30AM
Dec-03-21 09:00PM
Dec-02-21 10:02PM
Dec-01-21 04:30PM
04:26PM
11:00AM
Nov-30-21 05:34PM
12:41PM
07:30AM
Nov-15-21 03:40PM
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Echelard YannDirectorJan 06Buy10.649,00095,760201,848Jan 06 05:01 PM
Charney Laurence NDirectorJan 04Sale11.1030,000333,000234,729Jan 06 05:00 PM